Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): The NEOMUN trial
Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann, Martin E. Eichhorn
Research output: Contribution to journal › Article › peer-review
55Scopus
citations
Fingerprint
Dive into the research topics of 'Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): The NEOMUN trial'. Together they form a unique fingerprint.